Celsion Corp. Company Profile (NASDAQ:CLSN)

About Celsion Corp.

Celsion Corp. logoCelsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLSN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.26
  • 50 Day Moving Average: $1.24
  • 200 Day Moving Average: $1.36
  • 52-Week Range: $25,810,000.00 - $1.04
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.25
  • P/E Growth: 0.00
  • Market Cap: $32.52M
  • Outstanding Shares: 25,810,000
  • Beta: 2.36
Profitability:
  • Net Margins: -3,966.14%
  • Return on Equity: -103.07%
  • Return on Assets: -42.02%
Debt:
  • Current Ratio: 1.44%
  • Quick Ratio: 1.44%
Additional Links:
Companies Related to Celsion Corp.:

Analyst Ratings

Consensus Ratings for Celsion Corp. (NASDAQ:CLSN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (177.78% upside)

Analysts' Ratings History for Celsion Corp. (NASDAQ:CLSN)
Show:
DateFirmActionRatingPrice TargetDetails
9/15/2016Maxim GroupReiterated RatingBuy$4.00View Rating Details
7/12/2016HC WainwrightReiterated RatingBuy$3.00View Rating Details
11/24/2015Cantor FitzgeraldReiterated RatingNot Available -> BuyView Rating Details
7/13/2015BTIG ResearchInitiated CoverageBuy$10.00View Rating Details
4/16/2015Griffin SecuritiesSet Price TargetBuy$7.00View Rating Details
10/30/2014Canaccord GenuityInitiated CoverageBuy$7.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Celsion Corp. (NASDAQ:CLSN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/15/2016Q2($0.21)($0.19)ViewListenView Earnings Details
5/16/2016Q116($0.21)($0.24)ViewListenView Earnings Details
3/30/2016Q415($0.24)($0.24)ViewListenView Earnings Details
11/5/2015Q315($0.26)($0.20)ViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.27)ViewListenView Earnings Details
5/12/2015Q1($0.33)($0.34)ViewN/AView Earnings Details
3/12/2015($0.36)($0.32)ViewN/AView Earnings Details
11/12/2014($0.30)($0.35)ViewN/AView Earnings Details
8/7/2014Q214($0.32)($0.38)ViewN/AView Earnings Details
5/8/2014($0.24)($0.33)ViewN/AView Earnings Details
3/13/2014($0.28)($0.19)ViewN/AView Earnings Details
11/12/2013Q3($0.23)($0.30)$0.13 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)$0.01$0.13 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.12)ViewN/AView Earnings Details
11/12/2012Q312($0.17)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celsion Corp. (NASDAQ:CLSN)
Current Year EPS Consensus Estimate: $-0.83 EPS
Next Year EPS Consensus Estimate: $-0.56 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.17)($0.17)($0.17)
Q4 20161($0.17)($0.17)($0.17)
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion Corp. (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celsion Corp. (NASDAQ:CLSN)
Insider Ownership Percentage: 7.96%
Institutional Ownership Percentage: 15.19%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Alberto R Martinez JrDirectorBuy5,000$1.25$6,250.00View SEC Filing  
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.00View SEC Filing  
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00View SEC Filing  
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00View SEC Filing  
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00View SEC Filing  
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.00View SEC Filing  
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00View SEC Filing  
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00View SEC Filing  
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.48View SEC Filing  
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.00View SEC Filing  
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.00View SEC Filing  
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.00View SEC Filing  
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.00View SEC Filing  
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.00View SEC Filing  
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.00View SEC Filing  
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.00View SEC Filing  
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.00View SEC Filing  
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00View SEC Filing  
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celsion Corp. (NASDAQ:CLSN)
DateHeadline
News IconKeen Investors Find News on Celsion Corp. (NASDAQ:CLSN) - Duncan Research (NASDAQ:CLSN)
www.duncanindependent.com - September 23 at 3:40 PM
News IconUnder the Microscope, Zeroing in at Celsion Corp. (NASDAQ:CLSN) - Duncan Research (NASDAQ:CLSN)
www.duncanindependent.com - September 22 at 4:25 PM
News IconPenny Stock Investors Take an Interest in Celsion Corp. (NASDAQ:CLSN) - Duncan Research (NASDAQ:CLSN)
www.duncanindependent.com - September 21 at 8:19 AM
News IconNow Available: Celsion Corporation (CLSN) - Medical Equipment - Deals and Alliances Profile (NASDAQ:CLSN)
reports.pr-inside.com - September 16 at 4:08 PM
smarteranalyst.com logoCompany Update (NASDAQ:CLSN): Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION ... - Smarter Analyst (NASDAQ:CLSN)
www.smarteranalyst.com - September 15 at 4:39 PM
globenewswire.com logoCelsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer (NASDAQ:CLSN)
globenewswire.com - September 15 at 10:35 AM
streetinsider.com logoCelsion (CLSN) Reports DSMB Completed Safety Review of Data from Phase 1b OVATION Study in Ovarian Cancer (NASDAQ:CLSN)
www.streetinsider.com - September 15 at 10:35 AM
News IconThermoDox plus RFA may significantly improve survival of primary liver cancer patients (NASDAQ:CLSN)
www.dotmed.com - September 14 at 4:21 PM
benzinga.com logoCelsion Corporation Announces Independent NIH... (NASDAQ:CLSN)
www.benzinga.com - September 13 at 9:07 AM
streetinsider.com logoCelsion (CLSN) Announces Substantial Data from Independent NIH Analysis of HEAT Study (NASDAQ:CLSN)
www.streetinsider.com - September 13 at 9:07 AM
capitalcube.com logoETF’s with exposure to Celsion Corp. : September 12, 2016 (NASDAQ:CLSN)
www.capitalcube.com - September 12 at 4:07 PM
streetinsider.com logoCelsion (CLSN) Announces Substantial Data from Independent NIH Analysis of HEAT Study - StreetInsider.com (NASDAQ:CLSN)
www.streetinsider.com - September 12 at 9:04 AM
biz.yahoo.com logoCELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CLSN)
biz.yahoo.com - September 9 at 9:05 AM
News IconSell-side is Weighing in on Celsion Corporation (NASDAQ:CLSN) Earnings - Frisco Fastball (NASDAQ:CLSN)
friscofastball.com - September 8 at 5:13 AM
globenewswire.com logoCelsion Corporation to Present at Upcoming Investor Conferences - GlobeNewswire (press release) (NASDAQ:CLSN)
globenewswire.com - September 7 at 8:05 AM
finance.yahoo.com logoCelsion Corporation to Present at Upcoming Investor Conferences (NASDAQ:CLSN)
finance.yahoo.com - September 7 at 8:05 AM
News IconStock in Review: Taking a Closer Look at Celsion Corporation (NASDAQ:CLSN) Shares - Post News (NASDAQ:CLSN)
www.kentuckypostnews.com - September 2 at 9:05 AM
capitalcube.com logoETF’s with exposure to Celsion Corp. : August 30, 2016 (NASDAQ:CLSN)
www.capitalcube.com - August 30 at 4:17 PM
capitalcube.com logoETF’s with exposure to Celsion Corp. : August 30, 2016 (NASDAQ:CLSN)
www.capitalcube.com - August 30 at 4:17 PM
realistinvestor.com logoCelsion Corporation (NASDAQ:CLSN) Is Expected To Post EPS Of $-0.12 - RealistInvestor.com (NASDAQ:CLSN)
www.realistinvestor.com - August 29 at 9:32 PM
finance.yahoo.com logoCELSION CORP Financials (NASDAQ:CLSN)
finance.yahoo.com - August 24 at 4:16 PM
News IconCrowd & Analysts Have Spoken: Celsion Corporation (NASDAQ:CLSN) Stock Update - Post News (NASDAQ:CLSN)
www.kentuckypostnews.com - August 22 at 9:00 AM
capitalcube.com logoETF’s with exposure to Celsion Corp. : August 19, 2016 (NASDAQ:CLSN)
www.capitalcube.com - August 19 at 3:21 PM
capitalcube.com logoCelsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 (NASDAQ:CLSN)
www.capitalcube.com - August 18 at 4:19 PM
News IconDirector of Celsion Corporation (NASDAQ:CLSN), Martinez Alberto R Jr, buys 5,000 shares worth $6,250 (NASDAQ:CLSN)
empowerednews.net - August 18 at 11:05 AM
realistinvestor.com logoAnalysts See Celsion Corporation (NASDAQ:CLSN) Reporting EPS Of $-0.14 - RealistInvestor.com (NASDAQ:CLSN)
www.realistinvestor.com - August 16 at 9:34 PM
News IconCelsion announces final overall survival data from ThermoDox HEAT study (NASDAQ:CLSN)
www.dotmed.com - August 16 at 4:22 PM
4-traders.com logoZhejiang Hisun Pharmaceutical : Hisun Pharmaceutical H1 Net Down 45% (NASDAQ:CLSN)
www.4-traders.com - August 16 at 8:59 AM
streetinsider.com logoCelsion (CLSN) Offers Updated ThermoDox HEAT Study Data; Notes Robust OS Results (NASDAQ:CLSN)
www.streetinsider.com - August 16 at 8:59 AM
investors.com logoCelsion liver cancer data underscores co's potential of its technology (NASDAQ:CLSN)
www.proactiveinvestors.com - August 15 at 11:32 AM
biz.yahoo.com logoCELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:CLSN)
biz.yahoo.com - August 15 at 11:32 AM
publicnow.com logoCelsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:CLSN)
www.publicnow.com - August 15 at 11:32 AM
finance.yahoo.com logoCelsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology ... (NASDAQ:CLSN)
finance.yahoo.com - August 10 at 5:20 AM
streetinsider.com logoCelsion (CLSN) Enters Expanded GEN-1 Partnership with Zhejiang Hisun Pharma - StreetInsider.com (NASDAQ:CLSN)
www.streetinsider.com - August 9 at 5:15 PM
nasdaq.com logoExpanded Partnership Provides Capacity and Cost Structure Supporting Celsion's Global Commercial Strategy for GEN-1 (NASDAQ:CLSN)
www.nasdaq.com - August 9 at 11:45 AM
publicnow.com logoCelsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy (NASDAQ:CLSN)
www.publicnow.com - August 9 at 11:45 AM
publicnow.com logoCelsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016 (NASDAQ:CLSN)
www.publicnow.com - August 8 at 9:06 AM
News IconGene Therapy (NASDAQ:CLSN)
www.wealthdaily.com - July 28 at 12:45 PM
4-traders.com logoCelsion : Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients (NASDAQ:CLSN)
www.4-traders.com - July 26 at 4:10 PM
News IconCelsion announces positive data from OVATION study (NASDAQ:CLSN)
www.dotmed.com - July 26 at 12:26 PM
streetinsider.com logoCelsion (CLSN) Announces Data from GEN-1 Phase 1b; One pCR Noted (NASDAQ:CLSN)
www.streetinsider.com - July 25 at 9:01 PM
publicnow.com logoCelsion Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients (NASDAQ:CLSN)
www.publicnow.com - July 25 at 8:28 AM
finance.yahoo.com logo8:05 am Celsion announces data from the immunotherapy study of newly diagnosed ovarian cancer patients (NASDAQ:CLSN)
finance.yahoo.com - July 25 at 8:05 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Celsion Corporation (NASDAQ:CLSN) - TGP (NASDAQ:CLSN)
telanaganapress.com - July 22 at 11:46 AM
News IconInsiders Increasing Positions in: Celsion Corp. (NASDAQ:CLSN) - Press Telegraph (NASDAQ:CLSN)
presstelegraph.com - July 21 at 9:48 PM
News IconCelsion Corporation (NASDAQ:CLSN) Shorts Decreased by 39.49% After Short Covering - Consumer Eagle (NASDAQ:CLSN)
www.consumereagle.com - July 20 at 5:24 PM
fiscalstandard.com logoBroker Outlook For Celsion Corporation (CLSN) - Fiscal Standard (NASDAQ:CLSN)
www.fiscalstandard.com - July 20 at 5:24 PM
capitalcube.com logoETF’s with exposure to Celsion Corp. : July 20, 2016 (NASDAQ:CLSN)
www.capitalcube.com - July 20 at 12:16 PM
News IconEquity Roundup: Stock Performance Focus on Celsion Corporation (NASDAQ:CLSN) - Press Telegraph (NASDAQ:CLSN)
presstelegraph.com - July 19 at 4:21 PM
news.cmlviz.com logoCelsion Corp. Realized Volatility Hits a Dropping Level - CML News (NASDAQ:CLSN)
news.cmlviz.com - July 19 at 4:21 PM

Social

Celsion Corp. (NASDAQ:CLSN) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff